TWST is the ticker symbol for Twist Bioscience Corp, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks TWST with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is TWST a good stock to buy?

13F Pro's AI ranking engine scores TWST at 33.9/100, ranked #2,372 of 2,960 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for TWST is available at https://13fpro.ai/company/TWST. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source TWST data?

All Twist Bioscience Corp fundamentals and ownership data come directly from SEC EDGAR. Twist Bioscience Corp files with the SEC under CIK 1581280. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Twist Bioscience Corp(TWST)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Twist Bioscience Corp (TWST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TWST at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,372 of 2,960 stocks — the bottom half of the AI-ranked universe. TWST scores in the top quartile across revenue growth (81.6). Areas of concern include balance sheet strength (10.8) and free cash flow (12.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Twist Bioscience Corp reports quarterly revenue of $118.4M, net income of $-35.1M, an operating margin of -30.6%. Top institutional holders of TWST by reported 13-F value include BlackRock, Artisan Partners Limited Partnership, FMR, based on the most recent SEC filings. TWST trades on the Nasdaq exchange and files with the SEC under CIK 1581280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TWST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Twist Bioscience Corp directly from SEC EDGAR.

AI Quality Score

33.9/100

AI Rank

#2,372

Revenue

$118.4M

Net Income

$-35.1M

Free Cash Flow

$-8.6M

Operating Margin

-30.6%

TWST key financials by period

Twist Bioscience Corp reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$376.6M	$-77.7M	-36.2%
FY 2024	10-K	$313.0M	$-208.7M	-70.6%
FY 2023	10-K	$245.1M	$-204.6M	-88.6%
FY 2022	10-K/A	$203.6M	$-217.9M	-115.3%
FY 2021	10-K/A	$132.3M	$-152.1M	-115.4%
FY 2020	10-K/A	$90.1M	$-139.9M	-155.5%

Institutions holding TWST

Institutional investors reporting a position in Twist Bioscience Corp on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	5,833,891	$600.2M	2026-06-30
Artisan Partners Limited Partnership	4,802,017	$494.0M	2026-06-30
FMR	4,703,044	$483.8M	2026-06-30
ARK Investment Management	4,549,803	$468.1M	2026-06-30
PRICE T ROWE ASSOCIATES	3,634,652	$373.9M	2026-06-30
STATE STREET	3,232,532	$332.6M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	2,824,989	$290.6M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	2,699,280	$277.7M	2026-06-30
EdgePoint Investment Group	2,521,635	$259.4M	2026-06-30
WILLIAM BLAIR INVESTMENT MANAGEMENT	2,174,594	$223.7M	2026-06-30